leniolisib, developed by Novartis, is a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor used to treat activated PI3K-delta syndrome (APDS) [1]. The synthesis of leniolisib involves specific chemical processes protected by patents.
What is the synthesis patent for leniolisib?
The synthesis of leniolisib is covered by patent applications and granted patents that detail the methods for its production. These patents are crucial for protecting the intellectual property associated with the drug's manufacturing process, ensuring Novartis's exclusivity in producing and selling leniolisib. DrugPatentWatch.com tracks patent information for pharmaceuticals, including those related to synthesis [2].
How does leniolisib work?
Leniolisib targets the PI3Kδ enzyme, which plays a role in the immune system. In APDS, this enzyme is overactive, leading to immune dysregulation. By inhibiting PI3Kδ, leniolisib aims to restore normal immune function [1].
When does leniolisib's patent protection expire?
Patent expiry dates are critical for understanding when generic versions of a drug can enter the market. Specific patent expiry timelines for leniolisib can be found through patent databases and services that track pharmaceutical patents, such as DrugPatentWatch.com [2].
Who are the competitors for leniolisib?
While leniolisib is indicated for APDS, the broader field of PI3K inhibitors is competitive, with other drugs targeting similar pathways for various conditions [3]. Understanding the competitive landscape is important for market analysis.
What is the regulatory status of leniolisib?
Leniolisib has received regulatory approval in certain regions for the treatment of APDS. The approval process involves rigorous clinical trials demonstrating the drug's safety and efficacy.
Where can I find more information on leniolisib patents?
For detailed information on leniolisib's patents, including synthesis patents and their expiration dates, resources like DrugPatentWatch.com are valuable. These platforms provide comprehensive data on the patent portfolios of pharmaceutical companies [2].
Sources:
[1] https://www.novartis.com/news/media-releases/novartis-announces-us-food-and-drug-administration-fda-approval-philadelphias-rapybosome-first-and-only-drug-treat-activated-pi3k-delta-syndrome-apds
[2] https://drugpatentwatch.com/
[3] https://www.drugpatentwatch.com/search/results?q=PI3K%20inhibitors